We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis
Application Note

Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis

Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis
Application Note

Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis

Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs, with surface plasmon resonance (SPR) becoming a core technology in many pharma and biotech settings for the identification of low-affinity fragment compounds.

ForteBio has recently introduced the next generation in SPR biosensor analysis for fragments, exclusively available on Pioneer systems. This Next Generation SPR consists of OneStep® and NeXtStep™ gradient injection technologies.

Download this application note to learn about ForteBio's Next Generation SPR, including:

  • Fragment screening with OneStep and NeXtStep Injection techniques
  • Comparison of OneStep and conventional SPR in FBDD
  • Advantage of OneStep Injections
  • NeXtStep direct competition fragment assay
  • Plus much more...
Advertisement